Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study
Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program
CORRECTION - Domestic Metals Engages ICP Securities Inc. for Automated Market Making Services and provides further details on the engagement of Michael Pound
